GO:0016579 protein deubiquitination: Genes & Methods

Protein deubiquitination (GO:0016579) is the biological process that removes one or more ubiquitin groups from a protein. Ubiquitination is a reversible post-translational modification in which ubiquitin is attached to lysine residues of target proteins; deubiquitination reverses this modification and is therefore central to the dynamic regulation of protein fate. The process is carried out by deubiquitinating enzymes (DUBs), which cleave ubiquitin from substrates or from polyubiquitin chains, thereby controlling protein stability, localization, and activity. Because ubiquitination and deubiquitination are tightly coupled, deubiquitination is essential for proteasome-dependent degradation, ubiquitin recycling, and signaling homeostasis. For researchers, GO:0016579 is a high-value term because it sits at the intersection of protein quality control, cell-cycle regulation, and disease. For example, deubiquitination of CDC6 by OTUD6A promotes tumour progression and chemoresistance, while inhibition of the deubiquitylating enzyme RPN11 ameliorates nonalcoholic fatty liver disease. Cardiomyocyte-enriched USP20 ameliorates pathological cardiac hypertrophy by targeting STAT3 deubiquitination, whereas OTUD1 promotes pathological cardiac remodeling and heart failure by targeting STAT3. USP20 also deubiquitinates and stabilizes the reticulophagy receptor RETREG1/FAM134B to drive reticulophagy, and USP7 deubiquitinates KRAS to promote non-small cell lung cancer. These examples illustrate why GO:0016579 is a recurring theme in cancer, metabolic, and cardiovascular research. Understanding protein deubiquitination requires integrating structural biology, enzymology, and cell-based models. The 26S proteasome provides a structural and functional framework for how ubiquitinated substrates are recognized and processed, and early genetic studies established ubiquitin-dependent degradation as a fundamental regulatory system. This article summarizes the definition, mechanism, key genes, disease links, and research methods for GO:0016579, with a focus on how CRISPR models can be used to test causality.

Protein deubiquitination (GO:0016579) is defined as the removal of one or more ubiquitin groups from a protein. In practice, this means that a DUB enzyme cleaves the bond that attaches ubiquitin to a substrate lysine or to another ubiquitin molecule, reversing ubiquitination and changing the substrate's stability, interactions, or activity. The term covers removal of a single ubiquitin (mono-deubiquitination) as well as trimming or disassembly of polyubiquitin chains.

Protein deubiquitination is important because it provides the reversible counterbalance to ubiquitination, allowing cells to fine-tune protein lifetimes and signaling outputs. Without deubiquitination, ubiquitin pools would be depleted, degradation would be unchecked, and dynamic processes such as cell-cycle progression, stress responses, and receptor signaling would be impaired. In disease, altered deubiquitination can drive tumour progression and chemoresistance, metabolic dysfunction, cardiac hypertrophy and heart failure, reticulophagy dysregulation, and lung cancer. As a result, DUBs and their substrates are attractive targets for mechanistic studies and therapeutic development.

The following genes and proteins are experimentally linked to protein deubiquitination (GO:0016579) and its disease connections.

Protein deubiquitination is regulated at multiple levels, including DUB expression, post-translational modification, substrate availability, and interaction with adaptor proteins. The process is also coupled to the proteasome, where substrate recognition and deubiquitination are coordinated to control degradation efficiency. In disease contexts, DUB activity can be modulated by signaling pathways; for example, USP20 and OTUD1 regulate STAT3 deubiquitination in cardiomyocytes, and RPN11 inhibition alters metabolic pathways in nonalcoholic fatty liver disease. These examples indicate that deubiquitination is not a constitutive housekeeping event but a regulated node in cellular signaling.

Deubiquitination can stabilize oncoproteins or replication factors that promote tumour growth. OTUD6A deubiquitinates CDC6 and promotes tumour progression and chemoresistance, while USP7 deubiquitinates KRAS and promotes non-small cell lung cancer. These findings link GO:0016579 directly to cancer cell proliferation and therapy resistance.

Inhibition of the deubiquitylating enzyme RPN11 ameliorates nonalcoholic fatty liver disease, indicating that deubiquitination contributes to metabolic pathology. This connects GO:0016579 to lipid metabolism and liver disease research.

Cardiomyocyte-enriched USP20 ameliorates pathological cardiac hypertrophy by targeting STAT3 deubiquitination, whereas OTUD1 promotes pathological cardiac remodeling and heart failure by targeting STAT3. These opposing roles highlight the importance of deubiquitination balance in heart disease.

USP20 deubiquitinates and stabilizes the reticulophagy receptor RETREG1/FAM134B to drive reticulophagy. This links GO:0016579 to selective autophagy and endoplasmic reticulum turnover.

Mass spectrometry-based ubiquitin proteomics can identify ubiquitinated substrates and map the sites that are removed by deubiquitination. This approach is useful for defining the substrate spectrum of a DUB and for comparing wild-type and knockout cells.

Western blotting with ubiquitin or substrate-specific antibodies can detect changes in ubiquitination status after DUB manipulation. Chain-specific antibodies can further distinguish between linkage types and reveal how deubiquitination edits the ubiquitin signal.

Fluorescence imaging of tagged DUBs and substrates can show where deubiquitination occurs and how it affects protein localization. Tagged knock-in models are particularly useful for tracking endogenous proteins.

Cell proliferation, chemoresistance, lipid accumulation, cardiomyocyte hypertrophy, and reticulophagy assays can test the consequences of deubiquitination. These assays connect molecular changes to disease-relevant outcomes.

Researchers studying protein deubiquitination-related genes often need to determine whether a candidate gene is causally involved in a disease phenotype, which substrates it controls, and whether its catalytic activity is required. CRISPR-based models provide a direct way to test these questions by removing, mutating, tagging, or overexpressing the gene of interest in relevant cell types.

Protein deubiquitination (GO:0016579) is a core biological process that reverses ubiquitination and controls protein stability, localization, and signaling. Its importance is underscored by disease links involving OTUD6A, RPN11, USP20, OTUD1, USP7, and RETREG1/FAM134B in cancer, metabolic disease, cardiac disease, and autophagy. Studying this process requires a combination of biochemical, proteomic, imaging, and CRISPR-based approaches. For researchers, GO:0016579 offers a rich mechanistic space where substrate identification, enzyme specificity, and disease causality can be tested directly. CRISPR knockout, point mutation, knock-in, and overexpression models are well suited to dissect these questions and to translate deubiquitination biology into therapeutic hypotheses.